EXPERT Q&A: Is Merck’s COVID-19 pill molnupiravir a game-changer?
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
The Federal government has bought 300,000 doses of Merck COVID-19 treatment drug molnupiravir, although it has not yet been approved by the TGA as a COVID-19 treatment. On Friday the manufacturer announced in a press release data from an interim analysis of an ongoing phase-3 trial of molnupiravir in patients with mild to moderate COVID-19. Below an Australian expert explains what we know about the drug and what it means for vaccines.
Organisation/s: Monash University
Funder: N/A
Attachments:
Note: Not all attachments are visible to the general public
News for:
Australia
International
VIC
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.
Dr Vinod Balasubramaniam is a virologist at the Jeffrey Cheah School of Medicine & Health Sciences at Monash University in Malaysia